KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Total Non-Current Liabilities (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Total Non-Current Liabilities for 17 consecutive years, with $66.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 7.33% to $66.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $66.5 billion, a 7.33% decrease, with the full-year FY2025 number at $66.5 billion, down 7.33% from a year prior.
  • Total Non-Current Liabilities was $66.5 billion for Q4 2025 at Bristol Myers Squibb, up from -$24.0 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $132.6 billion in Q3 2024 to a low of -$24.0 billion in Q3 2025.
  • A 5-year average of $59.8 billion and a median of $66.3 billion in 2021 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: surged 1426.06% in 2024, then tumbled 118.11% in 2025.
  • Bristol Myers Squibb's Total Non-Current Liabilities stood at $66.0 billion in 2021, then fell by 10.4% to $59.1 billion in 2022, then rose by 0.24% to $59.3 billion in 2023, then rose by 21.08% to $71.7 billion in 2024, then dropped by 7.33% to $66.5 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Total Non-Current Liabilities are $66.5 billion (Q4 2025), -$24.0 billion (Q3 2025), and $72.2 billion (Q2 2025).